



Australian Government

Department of Health and Aged Care

Therapeutic Goods Administration

Case Line Listing

You searched for the following:

Report Date: >=2/09/2022 <=22/03/2023

Case Decision: Accepted

Characterisation: Suspect,Interacting

Ingredient Name: cannabidiol,tetrahydrocannabinol,Tetrahydrocannabinol (THC),Cannabidiol 125mg CBD in 2.98g of gel,Cannabidivarin,CANNABINOL

Number of Reports: 30

27 March 2023

Page 1 of 4

© Commonwealth of Australia 2017.

This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and enquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to <tga.copyright@tga.gov.au>.

Limitations of the data

This document contains information from reports of adverse events that the TGA has received in relation to therapeutic goods. It does not contain all known information, and an assessment of the safety of a medicine cannot be made based on this information.

Causality

- The reports received by the TGA contain suspected associations that reflect the observations of an individual reporter. The reporter may be a health professional, a sponsor, or a member of the public.
- Adverse events are suspected of being related to a therapeutic good, but this relationship is usually not certain - the symptom may be related to the underlying illness or to other factors.
- There might be no relationship between the adverse event and the medicine - it may be a coincidence that the adverse event occurred when the medicine was taken.

Case no.	Report Date	Sex	Age	Medicine (Onset Time in Days)	Reaction
751117	05/09/2022	Male	28	[REDACTED] (cannabidiol ; tetrahydrocannabinol) - Suspect [REDACTED]	Clumsiness
751122	05/09/2022	Male	62	[REDACTED] (cannabidiol ; tetrahydrocannabinol) - Suspect [REDACTED]	Vomiting
753785	03/10/2022	Male	33	[REDACTED] (cannabidiol) - Suspect [REDACTED]	Nausea
753786	03/10/2022	Female	20	[REDACTED] (cannabidiol ; tetrahydrocannabinol) - Suspect [REDACTED]	Abdominal discomfort; Somnolence
754987	14/10/2022	Female	72	[REDACTED] (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect [REDACTED]	Vertigo
754991	14/10/2022	Male	29	[REDACTED] (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect [REDACTED]	Sleep disorder
755228	17/10/2022	Female	48	[REDACTED] (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect [REDACTED]	Dry mouth; Nausea
755343	18/10/2022	Male	52	Trade Name Not Specified (tetrahydrocannabinol) - Suspect [REDACTED]	Mania
755583	20/10/2022	Male	52	Trade Name Not Specified (tetrahydrocannabinol) - Suspect [REDACTED]	Mania
756118	25/10/2022	Male	-	[REDACTED] (cannabidiol ; tetrahydrocannabinol) - Suspect [REDACTED]	Chest discomfort; Headache
758600	21/11/2022	Male	54	[REDACTED] (cannabidiol ; Tetrahydrocannabinol (THC)) - Suspect [REDACTED]	Arthralgia; Diarrhoea; Gastroesophageal reflux disease; Joint stiffness
759323	28/11/2022	Unspecified	50	[REDACTED] (cannabidiol ; tetrahydrocannabinol) - Suspect [REDACTED]	Diarrhoea
761725	12/12/2022	Male	60	[REDACTED] (cannabidiol ; tetrahydrocannabinol) - Suspect [REDACTED]	Drug ineffective
762095	15/12/2022	Male	17	[REDACTED] (cannabidiol ; tetrahydrocannabinol) - Suspect [REDACTED]; Trade Name Not Specified (clonidine) - Concomitant [REDACTED]; Trade Name Not Specified (fluoxetine hydrochloride) - Suspect [REDACTED]; Trade Name Not Specified (loratadine) - Concomitant [REDACTED]; Trade Name Not Specified (risperidone) - Concomitant [REDACTED]	Agitation; Akathisia; Condition aggravated; Drug interaction; Drug-genetic interaction; Insomnia; Mydriasis; Obsessive-compulsive disorder; Psychomotor hyperactivity
763516	03/01/2023	-	-	[REDACTED] (cannabidiol ; tetrahydrocannabinol) - Suspect [REDACTED]	Product complaint; Product packaging quantity issue
763783	05/01/2023	Unspecified	50	[REDACTED] (celecoxib) - Suspect [REDACTED]; [REDACTED] (cannabidiol) - Suspect [REDACTED]; [REDACTED] (cannabidiol ; tetrahydrocannabinol) - Suspect [REDACTED]	Abdominal pain upper; Aptyalism; Depression; Dry mouth; Dysgeusia; Dysphagia; Gastroesophageal reflux disease; Hangover; Lymphadenopathy; Oral pain; Sleep disorder; Swollen tongue; Tongue discolouration; Vomiting
763928	09/01/2023	Female	60	[REDACTED] (cannabidiol ; tetrahydrocannabinol) - Suspect [REDACTED]	Gastritis; Syncope

764560	17/01/2023	Male	17	(cannabidiol) - Suspect	Drug ineffective
765171	25/01/2023	Male	30	(cannabidiol ; delta-9-tetrahydrocannabinol) - Suspect	Cannabinoid hyperemesis syndrome
765883	03/02/2023	Male	17	(cannabidiol) - Suspect	Diarrhoea
766283	09/02/2023	Female	-	(cannabidiol ; tetrahydrocannabinol) - Suspect ; (cannabidiol ; tetrahydrocannabinol) - Suspect ; (cannabidiol ; tetrahydrocannabinol) - Suspect ; Trade Name Not Specified (buprenorphine) - Suspect ; Trade Name Not Specified (cefalexin) - Suspect ; Trade Name Not Specified (diazepam) - Suspect ; Trade Name Not Specified (domperidone) - Suspect ; Trade Name Not Specified (fluticasone furoate ; umeclidinium ; vilanterol) - Suspect ; Trade Name Not Specified (macrogol 3350 ; potassium chloride ; sodium bicarbonate ; sodium chloride) - Suspect ; Trade Name Not Specified (nicotine) - Suspect ; Trade Name Not Specified (ondansetron) - Suspect ; Trade Name Not Specified (pantoprazole) - Suspect ; Trade Name Not Specified (paroxetine) - Suspect	Abdominal distension; Anal incontinence; Asthenia; Blood magnesium decreased; Constipation; Dehydration; Gastritis; Haemorrhage; Loss of consciousness; Muscle spasms; Musculoskeletal stiffness; Nerve injury; Panic attack; Psychotic disorder; Shock; Urinary incontinence; Vasodilatation; Vision blurred; Vomiting
766523	13/02/2023	Male	29	(cannabidiol ; tetrahydrocannabinol) - Suspect	Psychotic disorder
767163	21/02/2023	Female	51	(cannabidiol) - Suspect	Condition aggravated; Insomnia
767185	21/02/2023	Male	51	(cannabidiol) - Suspect	Insomnia
767447	24/02/2023	Female	49	(cannabidiol ; tetrahydrocannabinol) - Suspect ; Trade Name Not Specified (lithium) - Concomitant ; Trade Name Not Specified (meloxicam) - Suspect ; Trade Name Not Specified (olanzapine) - Concomitant	Rash; Swelling face
767922	01/03/2023	Female	53	(cannabidiol) - Suspect	Headache; Pain
768730	09/03/2023	Male	83	(cannabidiol) - Suspect	Hypersensitivity
769619	20/03/2023	Female	25	(cannabidiol ; tetrahydrocannabinol) - Suspect	Coordination abnormal; Hypoaesthesia; Palpitations; Panic attack; Taste disorder
769681	20/03/2023	Male	42	(cannabidiol ; delta-9-tetrahydrocannabinol) - Suspect	Pulmonary embolism
769759	21/03/2023	Female	49	(cannabidiol ; delta-9-tetrahydrocannabinol) - Suspect	Anxiety; Dizziness; Sinus tachycardia; Swollen tongue